Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 15, 2024

Neoadjuvant Nivolumab With or Without Relatlimab for Resectable NSCLC

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial
Nat. Med. 2024 Apr 30;[EPub Ahead of Print], M Schuler, K Cuppens, T Plönes, M Wiesweg, B Du Pont, B Hegedus, J Köster, F Mairinger, K Darwiche, A Paschen, B Maes, M Vanbockrijck, D Lähnemann, F Zhao, H Hautzel, D Theegarten, K Hartemink, H Reis, P Baas, A Schramm, C Aigner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading